文献速递药物不良反应与药物警戒特殊人群用药

丙戊酸盐孕期暴露后神经发育结局报告的时间趋势:ConcePTION项目贡献

Temporal Changes in Reporting of Neurodevelopmental Outcomes After Maternal Exposure to Valproate: A Contribution of the ConcePTION Project.
PubMed 文献 · Drug Saf · 2025-07-07

本研究利用VigiBase数据库,分析孕期丙戊酸盐暴露后子代神经发育结局报告数量及事件聚类随时间的变化,并评估重要科学文献和监管决策的影响。结果显示,相关报告数量增加且不良事件模式更多样,关键文献与监管指南发布后报告数上升,但这些因素对增幅的贡献程度尚不明确。

要点

  • 孕期丙戊酸盐暴露后子代神经发育结局的报告数量随时间增加。
  • 重要文献和监管决策发布后,相关报告数量出现上升。
  • 报告增加与认知提升有关,但因果贡献程度尚不明确。

核心结论

  • 孕期丙戊酸盐暴露与子代神经发育结局相关的报告数量随时间增加,报告意识提升。
  • 重要出版物和监管决策后报告数上升,但其对观察到的增长贡献程度仍不清楚。

研究设计与样本

  • 观察性研究,使用VigiBase数据库,纳入从建库至2023年4月3日的报告,采用VigiBase妊娠算法识别。
  • 通过时间趋势图展示报告行为变化,关注重要科学出版物和监管决策的影响。
  • 采用vigiGroup方法识别报告聚类,由三名合格评审员独立审查临床相关性。

主要发现

  • 随时间推移,提及神经发育结局的报告数量增加,丙戊酸盐的不良事件模式更加多样化。
  • 关键出版物和国际监管指南发布后,报告数量可见增加。

局限性

  • 这些发展对观察到的报告增加的具体贡献程度尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Understanding changes over time in the quantity and characteristics of reports submitted to pharmacovigilance centres is crucial for accurately interpreting safety signals associated with exposure during pregnancy. OBJECTIVE: We aimed to assess temporal changes in the outcome measures for signal detection, specifically the number and clustering of reported adverse events concerning maternal valproate exposure and neurodevelopmental outcomes in offspring. METHODS: An observational study using VigiBase analysed changes in the number of reports and event clustering related to neurodevelopmental outcomes in offspring following valproate exposure during pregnancy. Reports from the start of VigiBase till 3 April, 2023 were identified using the VigiBase pregnancy algorithm. Time trend graphs illustrated reporting behavioural changes, with particular focus on the impact of major scientific publications and regulatory decisions. Report clusters, identified by the vigiGroup method, were randomised and independently reviewed by three qualified reviewers for clinical relevance to neurodevelopmental outcomes, morphological disorders or other entities. RESULTS: Over time, an increase in reports mentioning neurodevelopmental outcomes and a more diverse pattern of adverse events for valproate has been reported. An increase in the number of reports following key publications and international regulatory guidelines was visible. CONCLUSIONS: Our study revealed an increase over time in reporting and awareness of neurodevelopmental outcomes and valproate exposure during pregnancy, following important publications and regulatory decisions. However, the extent to which these developments contributed to the observed increase remains unclear.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Gkolfi D, van Rijt-Weetink YRJ, Taavola-Gustafsson H, et al. Temporal Changes in Reporting of Neurodevelopmental Outcomes After Maternal Exposure to Valproate: A Contribution of the ConcePTION Project. Drug Saf. 2025. PMID: 40624327. doi:10.1007/s40264-025-01583-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。